PDL1

ASCENT-04 Study: TROP2 ADC SG Combined with Keytruda Establishes New First-Line Standard for PDL1+ Triple-Negative Breast Cancer

by
ASCENT-04 Study: TROP2 ADC SG Combined with Keytruda Establishes New First-Line Standard for PDL1+ Triple-Negative Breast Cancer

The ASCENT-04 study is a global, multicenter, randomized, open-label phase III clinical trial designed to evaluate the efficacy and safety of the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab govitecan (SG) combined with the PD-1 inhibitor pembrolizumab (Keytruda, K drug) compared to chemotherapy combined with K drug in first-line treatment of PD-L1 positive (CPS≥10) metastatic triple-negative breast … Read more

New Antitumor Drug – PDL1 ADC

by
New Antitumor Drug - PDL1 ADC

Antibody-drug conjugates (ADCs) in antitumor therapy, also known as “biological missiles,” are a new type of drug that combines targeting and antitumor activity. By linking cytotoxic drugs to targeted drugs, when the targeted drug acts on the corresponding target, the drug enters the tumor cells through phagocytosis, causing lysis and releasing the cytotoxic drug to … Read more